摘要
Background and Aims:The World Health Organization(WHO)Western Pacific Region set a target of eliminating mother-to-child transmission(MTCT)of hepatitis B virus(HBV)by 2030.To assess the feasibility of this target in China,we carried out an epidemiological study to investigate the status quo of MTCT in the real-world setting.Methods:One thousand and eight hepatitis B surface antigen-positive preg-nant women were enrolled at 10 hospitals.Immunoprophy-laxis was administered to infants.In addition,mothers with HBV DNA level>2,000,000 IU/mL were advised to initiate antiviral therapy during late pregnancy.A health application called SHIELD was used to manage the study.Results:Nine hundred and five of the enrolled mothers,with 924 infants,completed the follow-up.Birth-dose hepatitis B vaccine and hepatitis B immunoglobulin were received by 99.7%and 99.7%of infants,respectively,within 24 h after birth.There ;were 446 mothers who received antiviral therapy,including 72.3%of the mothers with HBV DNA level>2,000,000 IU/mL and 21.0%of the mothers with HBV DNA level<2,000,000 IU/mL.Eight infants were infected with HBV.The overall rate of MTCT was 0.9%.Birth defects were rare(0.5%among in-fants with maternal antiviral exposure versus 0.7%among infants without exposure;p=1.00).Conclusions:The MTCT rate was lower than the WHO Western Pacific Region elimina-tion MTCT target in this real-world study,indicating that a comprehensive management composed of immunoprophy-laxis to infants and antiviral prophylaxis to mothers may be a feasible strategy to achieve the 2030 WHO elimination goal.
基金
the China Foundation for Hepatitis Prevention and Control(CFHPC)and National Natural Science Foundation of China(Grant No.81673243)
the Chinese National Research Grant of the Thirteenth Five-Year Plan for the Key Projects in Infectious Diseases(Grant No.2017ZX10201201).
作者简介
Corresponding author:Zhihua Liu,Hepatology Unit,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong 510515,China.Tel:+86-20-62787432,Fax:+86-20-62786530,E-mail:zhihualiu@126.com;Corresponding author:Jinlin Hou,Hepatology Unit,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong,510515,China.Tel:+86-20-61641941,Fax:+86-20-62786530,E-mail:jlhousmu@163.com
